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Background: Public pressure has increasingly emphasized the need to ensure the continuing quality of care
provided by health professionals over their careers. Health profession’s regulatory authorities, mandated to be
publicly accountable for safe and effective care, are revising their quality assurance programs to focus on regular
evaluations of practitioner performance. New methods for routine screening of performance are required and the
use of administrative data for measuring performance on quality of care indicators has been suggested as one
attractive option. Preliminary studies have shown that community pharmacy claims databases contain the
information required to operationalize quality of care indicators. The purpose of this project was to determine the
feasibility of routine use of information from these databases by regulatory authorities to screen the quality of care
provided at community pharmacies.
Methods: Information from the Canadian province of Quebec’s medication insurance program provided data on
prescriptions dispensed in 2002 by more than 5000 pharmacists in 1799 community pharmacies. Pharmacy-specific
performance rates were calculated on four quality of care indicators: two safety indicators (dispensing of contra-
indicated benzodiazepines to seniors and dispensing of nonselective beta-blockers to patients with respiratory
disease) and two effectiveness indicators (dispensing asthma or hypertension medications to non-compliant
patients). Descriptive statistics were used to summarize performance.
Results: Reliable estimates of performance could be obtained for more than 90% of pharmacies. The average rate
of dispensing was 4.3% (range 0 - 42.5%) for contra-indicated benzodiazepines, 15.2% (range 0 - 100%) for
nonselective beta-blockers to respiratory patients, 10.7% (range 0 - 70%) for hypertension medications to
noncompliant patients, and 43.3% (0 - 91.6%) for short-acting beta-agonists in over-use situations. There were
modest correlations in performance across the four indicators. Nine pharmacies (0.5%) performed in the lowest
quartile in all four of the indicators, and 5.3% (n = 95) performed in the lowest quartile on three of four indicators.
Conclusions: Routinely collected pharmacy claims data can be used to monitor indicators of the quality of care
provided in community pharmacies, and may be useful in future to identify underperforming pharmacists, measure
the impact of policy changes and determine predictors of best practices.
Background
Although medications are a mainstay of modern medical
treatment, their use is associated with both benefit and
harm [1-3]. Preventable drug-related morbidity and
mortality (DRM) now accounts for 8% to 23% of hospi-
tal admissions in seniors [4-6]. In North America in the
early 1990’s, professional pharmacy organizations recog-
nized the extent of this problem and recommended that
pharmacists expand their role to include a focus on
minimizing preventable DRM [7-9]. This recommenda-
tion was based on the assertion that pharmacists are
both educated to manage patients’ drug-therapy
problems and readily accessible within the majority of
communities in North America. Indeed, the average
Canadian adult visits a community pharmacy once or
twice per month [10]. This situation provides an ideal
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patient’s preventable DRM.
As pharmacists have incorporated this role of mini-
mizing DRM into their practice, university-based educa-
tional programs have been modified to emphasize these
responsibilities and standards of practice have been
revised [11,12]. Increasing public emphasis on the need
for assurance that health practitioners remain competent
to provide quality care through out their careers has
lead pharmacy regulatory authorities to update their
programs for monitoring pharmacist’s performance to
ensure compliance with these revised standards of prac-
tice [personal communications Quebec Order of Phar-
macists and Nova Scotia College of Pharmacists]. These
quality assurance programs are being updated based on
modern frameworks for regulatory review that include
proactive routine surveillance of practice performance,
followed by more in-depth assessment of potentially
under-performing practices [13-16]. Such frameworks
acknowledge the collaborative nature of current health
care provision and that the quality of care provided by
the health care team is dependent on the quality of care
provided by each team member [14,17]. These frame-
works are appropriate for use in community pharmacies,
where multiple pharmacists and pharmacy technicians
contribute to the care and services provided to an indi-
vidual patient [18,19]. Therefore, the proactive surveil-
lance phase of regulatory programs recommended for
community pharmacists measures performance on a
pharmacy-specific basis rather than on a pharmacist-
specific basis [14].
Indicators are being developed to conduct routine sur-
veillance of the quality of care provided in community
pharmacies [20]. To maximize efficiency, it has been
recommended that performance on these indicators be
assessed using pharmacy claims data that are routinely
collected as part of daily provision of medications and
services [14,20]. Preliminary studies have shown that the
data required to measure performance on these indica-
tors is available in pharmacy claims databases and that
pharmacists find comparative performance information
useful [21]. What remains to be evaluated is whether
routine use of information from these databases to mea-
sure performance at community pharmacies is feasible.
Feasibility can be determined by evaluating whether the
database-derived performance measures meet the key
requirements for use by regulatory authorities for qual-
ity assurance. Specifically, the target services need to be
routinely provided at the majority of community phar-
macies, care must be appropriately attributed, and there
must be sufficient variability in performance across
community pharmacies to warrant surveillance [22].
The purpose of this project was to determine the fea-
sibility of routine use of information from these
databases by regulatory authorities to screen the quality
of care provided at community pharmacies.
Methods
Context
This study was conducted in the Canadian province of
Quebec where the Order of Pharmacists, the govern-
mental regulatory authority responsible for licensing
pharmacists, monitors the performance of more than
5000 community pharmacists in 1800 community phar-
macies. These pharmacists serve a population of 7.4 mil-
lion patients, of whom approximately 50% receive
government support for payment of their medications
via the publicly-funded insurance program (Régie de
l’assurance maladie du Québec - RAMQ). Similar to
public and private insurance programs in the rest of the
Canadian provinces and American states, medication-
related data maintained by RAMQ for insured patients
includes payments made for each dispensing of a reim-
bursable medication, the date, the name, strength,
dosage form and quantity of the dispensed medication,
and prescriber, pharmacist and pharmacy identification.
Reimbursable medications include over 85% of medica-
tions available in Canada. In Quebec, medication supply
policies support dispensing of chronic medications on a
30 day interval rather than encouraging a 90 day dispen-
sing interval. Although this policy provides more oppor-
tunities for pharmacists to detect and intervene on
medication use problems, dispensing on either a 30 day
or 90 day interval provides regulatory authorities with
the data required to measure performance on quality of
care indicators.
Study Population
To assess the quality of care provided at community
pharmacies, we used a random sample of 1.4 million
patients who received medications from community
pharmacies between January and December 2002. In
addition to the routine medication-related information,
for each dispensing a unique anonymized identifier was
provided by RAMQ for each patient, prescriber and dis-
pensing pharmacy. These unique identifiers were used
to develop a longitudinal prescription history for each
patient and a practice population for each pharmacy
that could be used to measure quality of performance
on each indicator on a pharmacy-specific basis. Ethics
approval was obtained from the McGill Faculty of Medi-
cine Institutional Review Board.
Assessing Feasibility
The feasibility of using pharmacy claims data to evaluate
performance was assessed by calculating pharmacy-
specific performance on four quality of care indicators
and determining whether results met requirements for
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[22]. Specifically we evaluated the proportion of com-
munity pharmacies where provision of services was
frequent enough to allow reliable assessment on the per-
formance indicators, the variability of performance
across pharmacies and the proportion of pharmacies
where performance was systematically poor on multiple
indicators, indicating a need for further evaluation.
Selection and Measurement of Indicators
The Pharmacy Quality Alliance (PQA) in the United
States has developed quality indicators for conditions
where there are widely documented medication use pro-
blems, including noncompliance with anti-hypertensive
medications, over-use of rescue inhalers in the treat-
ment of asthma and use of contra-indicated/high risk
medications [20]. We used similar indicators to assess
performance at community pharmacies in Quebec. Two
of the indicators measured safety (the use of high risk
medications) and two represented effectiveness of
chronic treatments (hypertension and asthma)(Table 1).
To produce comparable measures of performance
among pharmacies, we restricted the denominator for
each indicator to the “at-risk” patient population. This
at-risk population was defined as patients who were
treated for the respective problem (e.g. hypertension) or
who had been dispensed medications within a specific
therapeutic class. For example, for the medication safety
indicator evaluating the dispensing of flurazepam to
seniors, the at-risk population was defined as ‘all seniors
who were dispensed a benzodiazepine from the phar-
macy’ and not as ‘all seniors dispensed a medication
from the pharmacy’ as most would not be using a ben-
zodiazepine and would, therefore, not be at-risk. Details
of the at-risk population used for each indicator are
found in Table 1.
Number of dispensings was counted in the numerator
and denominator because the number of dispensings
provided the best measure of the opportunity for com-
munity pharmacists to detect and intervene on medica-
tion-use problems. For example, for the indicator
evaluating non-compliance with anti-hypertensive
Table 1 Quality of Care Indicators for Community Pharmacists
Indicator Definition
Medication Safety
Beta Blockers in Respiratory Patients
Recommended Care: Patients receiving a SABA should not
receive nonselective beta-blockers (NSBB)
Measure: proportion of dispensings of beta-blockers to patients dispensed SABA that
are for NSBB*
Denominator: # of dispensings of oral beta-blockers (selective or nonselective) to
patients who received a SABA from any pharmacy within the previous 6 months
(including dispensing on the same day)
Numerator: # of dispensings of oral NSBB to patients who were dispensed a SABA
from any pharmacy within the previous 6 months (including dispensing on the same
day)
Benzodiazepines in the Elderly
Recommended Care: seniors requiring a benzodiazepine
should not receive long acting agents (flurazepam)
Measure: proportion of dispensings of benzodiazepines to patients >65 years old that
are for flurazepam*
Denominator: # of dispensings of benzodiazepines to patients >65 years old
Numerator: # of dispensings of flurazepam to patients >65 years old
Medication Effectiveness
Over-use of Asthma Medications
Recommended Care: patients should not use more than 250
doses of SABA in a 90 day period
Measure: proportion of dispensings of SABA that are provided to patients who had
used more than 250 doses of these rescue medications over the previous 90 days*
Denominator: # of dispensings of inhaled SABA
Numerator: # of dispensings of an inhaled SABA that were provided to a patient who
had been dispensed more than 250 doses of this same SABA from any pharmacy
within the previous 90 days
Under-use of Anti-hypertensives
Recommended Care: patients should take at least 80% of their
medication prescribed for hypertension
Measure: proportion of dispensings of anti-hypertensive medications that are
provided to patients who had received <80% of their required supply of
antihypertensive medications over the previous 90 days*
Denominator: # of dispensings of any blood pressure medications
Numerator: # of dispensings of any blood pressure medications that were to patients
who had received <80% of the prescribed amount of any blood pressure
medications over the previous 90 days from any pharmacy
* The lower the score on the Quality of Care indicators the better the performance.
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non-compliance each time a patient returned to the
pharmacy for a refill of his/her medication. Therefore,
each dispensing to a non-compliant patient represented
an opportunity for intervention by the pharmacist.
Pharmacy-specific performance on each quality indica-
tor was calculated using dispensings of medications
from all community pharmacies. All dispensings were
included because pharmacists are expected to inquire
about all prescription therapies including dispensings
from other pharmacies. Operationally this meant that
for the dispensing of concomitant non-selective beta-
blockers and inhaled short acting beta agonists (SABA),
the medications could be dispensed from two different
pharmacies and the performance was attributed to the
pharmacy dispensing the non-selective beta-blocker to
the patient. For the over-use of SABA and non-compli-
ance with anti-hypertensive medications, all SABA’sa n d
anti-hypertensives dispensed to the patient from all
pharmacies were counted. As medication discontinua-
tion and switching are not well documented in data-
bases and are common in management of hypertension,
the inclusion of all anti-hypertensives allowed us
to eliminate the problems of over-estimation of non-
compliance due to switching or changing dose of anti-
hypertensive medications.
To ensure stable estimates of performance we
required pharmacists at each pharmacy to dispense the
relevant medication to the at-risk population (i.e.
denominator group) five or more times over the one
year period [23]. Such cut offs are recommended for use
in measures of physician performance to improve the
reliability of estimated performance while ensuring that
potential poor-performers who provide a low volume of
service are not excluded from evaluations [22,24].
Data Analysis
To evaluate whether the performance on the quality
indicator met the requirements established by regulatory
authorities, we first determined the number of pharma-
cies where pharmacists provided the service frequently
enough for reliable performance estimates to be calcu-
lated. We then used univariate statistics and the coeffi-
cient of variation to examine the distribution of the
quality of performance across pharmacies. To determine
if performance on one indicator influenced performance
on another indicator, we estimated the Spearman Rank
Order Correlation among indicators using the pharmacy
as the unit of analysis. To estimate the proportion of
pharmacies that would be in the worst-performing quar-
tile in all indicators, and would likely be targeted for
regulatory review, we cross tabulated performance by
quartile on the four performance indicators.
Results
Our sample included 1,427,325 patients with an average
a g eo f5 0a n dap r e d o m i n a n c eo fw o m e n( T a b l e2 ) .
Patients were dispensed on average 6.2 different medi-
cations per year, receiving these medications via, on
average, 37.9 dispensings per year. The mean number
of pharmacies visited per patient per year was 1.6, with
61.4% of patients using one pharmacy exclusively over
the study period. Although within our study popula-
tion the greatest number of patients demonstrated
under-use of anti-hypertensive medications (42.5%,
220,179 of 517,656 at-risk patients under-used anti-
hypertensives), patients taking SABA were more likely
to demonstrate inappropriate use of these medications
(57.0%, 39,895 of 70,021 at-risk patients over-used
SABA).
Breadth and Frequency of Service Provision
The majority of pharmacies provided the services for the
four indicators frequently enough to be included in the
performance calculation (Table 3). The indicator that
excluded the greatest number of pharmacies was the
indicator measuring the concomitant use of SABA and
non-selective beta-blockers, reflecting the low preva-
lence of at-risk patients in the population (Table 2). For
the indicator related to under-use of anti-hypertensive
medications, virtually all pharmacies met the cut-off cri-
teria of having dispensed anti-hypertensive medications
five or more times over the study period. No pharmacy
was excluded from the performance calculation on all
four indicators.
Overall quality and variability in service provision
Overall the quality of performance was better for
the medication-safety indicators than for the medica-
tion-effectiveness indicators (Table 3). The worst perfor-
m a n c eo nt h ef o u rq u a l i t yo fc a r ei n d i c a t o r sw a s
exhibited for the SABA over-use indicator. On average,
across all pharmacies, 43.3% dispensings of SABA were
to patients who had over-used these medications within
the previous 90 days. Performance on the medication-
safety indicator measuring pharmacist dispensing of flur-
azepam to seniors was the best with, on average, 4.3
percent of benzodiazepine dispensings to seniors being
for flurazepam.
Variability of performance across the community phar-
macies on each of the indicators is also provided
in Table 3. Based on the coefficient of variation (CV), per-
formance on the medication-safety indicators demon-
strated the greatest variability. Across pharmacies the
rate of inappropriate dispensing ranged from 0% to
42.5% for flurazepam with a CV of 0.72, and 0% to 100%
for nonselective beta-blockers and SABA (CV = 0.73)
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Health Services Use Mean SD
Prescribing physicians per year 2.7 2.0
Dispensing pharmacies per year 1.6 0.95
N%
Patients receiving all medications & services from a single pharmacy per year 877,038 61.4
†
Population Prevalence of Quality of Care Problems N (N at-risk) % **
Medication Safety Indicators
Seniors receiving flurazepam 11,453 (196,774) 5.8
Patients receiving non-selective beta blockers and SABA 5,200 (33,058) 15.7
Medication Effectiveness Indicators
Patients over-using SABA 39,895 (70,021) 57.0
Patients under-using anti-hypertensives 220,179 (517,656) 42.5
† Percent of 1,427,325 patients.
‡ Calculated by determining the average of the total number of medications per patient per year.
§ Total number of dispensings in one year period is 54,045,097.
** Percent of the population at-risk.
Table 3 Pharmacy-Specific Performance on Quality of Care Indicators
Breadth/Frequency of
Performance



















Dispensings of benzodiazepines to seniors 1763 98.0 1,885,484 3.5 Seniors receiving flurazepam 4.3
§§ 3.1 0-42.5
Dispensings of beta-blockers to patients
taking SABA






Dispensings of SABA 1775 98.7 527,955 1.0 Patients over-using SABA 43.3
†††
12.4 0-91.6





†† Of all pharmacies dispensing medications in our sample (1799).
‡‡ Of all dispensings of medications to our population during 2002 (54,045,097).
§§ Median annual dispensing rate for flurazepam is 4.0%, interquartile range 2.5%-5.7%.
*** Median annual dispensing rate for SABA and non-selective beta-blockers is 14.2%, interquartile range 8.3%-20.4%.
††† Median annual dispensing rate for SABA over-use is 43.6%, interquartile range is 36.4%-50.7%.
‡‡‡ Median annual dispensing rate for HTN under-use is 10.2%, interquartile range is 8.4%-12.2%.
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cators, the CVs of the two indicators were lower (0.29 for
SABA over-use and 0.37 for anti-hypertensive under-use).
Performance across indicators
Among the 1799 pharmacies, 86% provided a sufficient
number of services to assess performance on all four
indicators. The rank order correlation among indicators
was modest, varying from -0.01 (nonselective beta-
blockers concomitant with SABA and over-use of
SABA) to a high of -0.13 (over-use of SABA and under-
use of anti-hypertensive medications).
Nine pharmacies performed in the lowest quartile on all
four indicators, with an additional 95 pharmacies perform-
ing in the lowest quartile on three of four indicators. These
pharmacies represent those that, in all likelihood, would be
targeted for further evaluation by regulatory authorities. By
contrast, three pharmacies were in the top quartile for all
four indicators with another 79 pharmacies in the top quar-
tile for three of four indicators. These pharmacies would be
useful to determine predictors of best practice.
Discussion
This study evaluated all 1800 community pharmacists
providing medications to 1.4 million people within the
jurisdiction of one regulatory authority in Canada. We
found that performance at community pharmacies could
be measured on four quality of care indicators using
pharmacy claims data. Over 85% of pharmacies provided
services frequently enough to be reliably assessed on all
four indicators. Proactive surveillance documented sub-
stantial variability in performance, with the best perfor-
mance demonstrated on the indicator measuring rates
of dispensing of contra-indicated benzodiazepines to the
elderly, and the worst performance demonstrated on the
dispensing of SABA to patients who were over-using
this medication. Pharmacists at 5.3% (95/1799) of phar-
macies underperformed on three of the four indicators.
T h i ss t u d yi st h ef i r s tt ob ed o n ei nC a n a d at h a tu s e s
routinely available claims data to evaluate performance
at community pharmacies. The PQA in the United
States has completed a series of demonstration projects
using administrative data from limited numbers of phar-
macies (25 to 85 community pharmacies) to evaluate
and report on pharmacy-based performance on quality
indicators measuring similar medication use-problems
[21]. Similar to our results, these projects indicate that
pharmacy claims data contain the information necessary
to measure a number of quality of care indicators and
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Figure 1 Distribution of Pharmacies by Performance on Safety and Effectiveness Indicators as Measured by Pharmacy Specific Percent
of Inappropriate Dispensings.
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stration projects is difficult, since limited performance
results have been published. However, differences in
results are anticipated as our project used different defi-
nitions for some indicators. For example, for SABA
over-use we used the Canadian guidelines that define
over-use as more than 250 doses in 90 days as prior
research had shown that overuse of this magnitude is
associated with an increased risk of asthma mortality
[25-27]. In contrast, the PQA defined over-use as more
than 600 doses in 90 days. As a result of these differ-
ences in quality definitions, performance results would
be worse in our study as compared to in the demonstra-
tion projects. To assess differences in jurisdictions and
pharmacy policies, it will be essential to use common
metrics for quality measurement.
Comparison of our results with those from the demon-
stration projects is also difficult as the PQA indicators use
patients as the unit of analysis where we elected to use dis-
pensings as the unit of analysis. Although number of
patients could have been used in our study, by doing so
we would have been unable to detect differences in phar-
macies where, for example, a patient was compliant for 11
of 12 dispensings as compared to a pharmacy where the
patient was compliant for none of the 12 dispensings. If
patients had been used as the unit of analysis, both
patients would have been classified as non-compliant for
the year and the performance of the two pharmacies con-
sidered to be equal. To create a more sensitive measure of
performance we, therefore, elected to use the number of
dispensings as the unit of analysis. Use of dispensings ver-
sus patients would also be anticipated to result in a greater
variability in performance across pharmacies, whereas use
of patients as the unit of analysis would provide an esti-
mate of the impact of pharmacy services in the population.
Both approaches will be useful to evaluate in the future.
The results of our work have significant implications
for regulatory authorities as the approach of using claims
data to measure performance on quality of care indica-
tors appears to be feasible and reveals substantial varia-
bility in the quality of care provided at community
pharmacies. With greater demand for public accounta-
bility for the quality of health professional practice,
regulatory authorities are moving from a passive com-
plaints-based process for monitoring to proactive quality
assurance. Currently, pharmacy regulatory authorities
have adopted very resource-intensive processes such as
on-site inspections or competence testing for assessing
the quality of practice [28-30]. Given limitations in avail-
ability of human resources, such processes are not able to
ensure timely detection of potential performance pro-
blems that require further investigation. The ubiquitous
availability of pharmacy claims data, and ultimately
electronic health records, and the reliability of this data
provides a new avenue for relatively inexpensive, proac-
tive performance assessment by regulatory authorities
[31]. The methodologies for performance monitoring
using billing and electronic health record data are being
developed in a number of sectors such as pay-for-perfor-
mance [32]. Pharmacy regulatory authorities will be able
to capitalize upon such advances while developing their
performance assessment programs. These approaches
may also be more acceptable to practitioners since they
are based on actual performance data rather than artifi-
cial testing or inspection processes [16].
The main strengths of this study are the large and
representative population of pharmacies studied and the
measurement of quality indicators in comparable popu-
lations. Limitations that shou l db ec o n s i d e r e di ni n t e r -
preting the results are that only four indicators were
evaluated that may not be representative of a phar-
macy’s quality of care, and the relationship between per-
formance on the indicator and patient outcome was not
ascertained. We were also missing data such as treat-
ment indication, and patient age, sex and socioeconomic
status, all of which could influence the types of drugs
prescribed and their utilization. In future it would be
preferable to retrieve information on these patient-
related characteristics to statistically adjust for differ-
ences in clientele served by different pharmacies. In
addition to these patient characteristics that may affect
pharmacy-specific performance, pharmacy-level charac-
teristics have also been shown to relate to the quality of
care provided in community pharmacies [33]. Future
work should evaluate the influence of these pharmacy-
level characteristics, such as pharmacy location, dispen-
sing volume and staffing, on the quality of care provided
at community pharmacies.
Our results confirm that patients present to commu-
nity pharmacies with evidence of well known medication
use problems that are related to safe and effective use of
medications. Patients at some pharmacies receive super-
ior care and our methodologies could be used to evaluate
the patient, pharmacy and prescriber-based characteris-
tics that are associated with better care. There are many
changes being made to the way services are being pro-
vided in community pharmacies such as regulation of
pharmacy technicians, remote dispensing and deregula-
tion of prescription medications. The utilization of phar-
macy claims data provides unique opportunities to
evaluate the influences of such policy changes.
Conclusion
Routinely collected pharmacy claims data can be used to
monitor indicators of quality of pharmacy services,
and may be useful in future to identify potentially under-
performing pharmacists, measure the impact of policy
changes and to determine predictors of best practices.
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